Steineger J, et al. - In a prospective, noncomparative study, experts evaluated the long-term impact of intranasal bevacizumab therapy in hereditary hemorrhagic telangiectasia (HHT). They included and followed patients who were treated for HHT-associated epistaxis by intranasal submucosal bevacizumab injections between June 2011 and August 2013. For most of the moderate and severe grades of HHT-associated epistaxis, intranasal bevacizumab injection was an effective treatment. Findings suggested a variable duration of the effect of the treatment. It was common to see primary and late resistance phenomena to the treatment.